Live Breaking News & Updates on Oncologist

Stay informed with the latest breaking news from Oncologist on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Oncologist and stay connected to the pulse of your community

Oncologist talks early detection after Kate Middleton diagnosis

The Princess of Wales announced she is undergoing chemotherapy on Friday. An oncologist explained the importance of early detection.

London , City-of , United-kingdom , Oncologist , Ancer , Etection , Arly , Ate-middleton , Rincess , Iagnosis , Reast-cancer

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

William-gradishar , Gregory-vidal , Rena-callahan , Mabel-mardones , Peer-exchange , European-society-for-medical-oncology-congress , Medical-oncology-congress , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances

The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.

Michigan , United-states , Matthew-pianko , Anthony-perissinotti , Ryan-haumschild , University-of-michigan-health , Practice-pearls , Michigan-health , Pharmacy-times , Physician-champion , Project-champion , Bispecific-antibodies

Author of Death Threats Against Oncologist Identified

The author of the death threats sent via social media to the head of Oncology in L'Aquila, Luciano Mutti, while he was...

Laquila , Abruzzo , Italy , Messina-denaro , Matteo-messina-denaro , Luciano-mutti , Mafia , District-anti-mafia , Uthor , Death , Threats , Against

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

William-gradishar , Mabel-mardones , Rena-callahan , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Rena-callahan , William-gradishar , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

British Punjabi doctor leads ground-breaking international trial of bowel cancer vaccine |

Other News News: A British Punjabi doctor is leading a ground-breaking international trial of a landmark vaccine to fight bowel cancer. The vaccine, designed by Imugene, will be tested on 44 patients across the UK and Australia. This trial could be a major breakthrough in bowel cancer treatment.

Australia , London , City-of , United-kingdom , Jalandhar , Punjab , India , Bilga , British , Tony-dhillon , Imperial-college-london , British-indian

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William-gradishar , Rena-callahan , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Breast-cancer , Clinical-guidelines , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive , Her2-negative , Selective-estrogen-receptor-degrader

The Situation Room With Wolf Blitzer

walter reed medical center. in the statement, they said that prostate cancer was detect early and his prognosis is excellent. on january 1 last monday, he was admitted to walter reed medical center with complications from the procedure , including nausea with severe abdominal, hip and leg pain. initial evaluation from that revealed that it was a urinary tract infection. the infection has since cleared and it involved various complications about abdominal fluid that was ultimately drained. rare complications and an oncologist told cnn, less than 1% of instances resulting from these kinds of prostate cancer surgeries. the pentagon still has not revealed why the white house was not made aware of secretary austin's prostate cancer diagnosis until today and depending on press secretary, general was asked today whose ideal it was.

Prostate-cancer , Complications , Statement , Procedure , Prognosis , Walter-reed-medical-center , On-january-1 , January-1 , 1 , Infection , Evaluation , Urinary-tract-infection